CNS neuroscience & therapeutics · 2026
Ocular Adverse Events Associated With Antidepressants: A Large-Scale Data Analysis From the FAERS Database.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peng Yiming, Cao Yichen, Liu Hanhan, Ma Junlong, Yang Guoping
Аннотация
OBJECTIVE: Global antidepressant use has risen substantially, raising concerns about their potential ocular adverse effects. Nevertheless, large-scale comprehensive assessments of ocular side effects associated with various classes of antidepressants remain limited.
METHODS: A retrospective pharmacovigilance analysis was performed using the FDA Adverse Event Reporting System (FAERS) from Q1 2015 to Q4 2024. Reports associated with antidepressants were systematically extracted, and disproportionality analyses were performed to identify potential associations with ocular adverse events (AEs).
RESULTS: 62,020 ocular AE reports were identified for 13,348 patients (median age, 44 years), with higher susceptibility observed in females. Norepinephrine-dopamine disinhibitors (NDDIs) showed the strongest association with eye disorders (IC 3.84, 95% CI 3.75-3.90), while selective serotonin reuptake inhibitors (SSRIs) showed the greatest number of positive associations across key ocular AEs. Analysis of the 36 antidepressants with sufficient case reports for ocular neuromuscular disorders revealed that 33 were associated with such disorders, most notably mydriasis, miosis, and anisocoria.
CONCLUSION: This study delineates the ocular risks of antidepressants, highlighting higher toxicity for NDDIs and SSRIs and widespread associations with ocular neuromuscular disorders. Vigilant monitoring and early intervention are warranted to ensure safe clinical use.
METHODS: A retrospective pharmacovigilance analysis was performed using the FDA Adverse Event Reporting System (FAERS) from Q1 2015 to Q4 2024. Reports associated with antidepressants were systematically extracted, and disproportionality analyses were performed to identify potential associations with ocular adverse events (AEs).
RESULTS: 62,020 ocular AE reports were identified for 13,348 patients (median age, 44 years), with higher susceptibility observed in females. Norepinephrine-dopamine disinhibitors (NDDIs) showed the strongest association with eye disorders (IC 3.84, 95% CI 3.75-3.90), while selective serotonin reuptake inhibitors (SSRIs) showed the greatest number of positive associations across key ocular AEs. Analysis of the 36 antidepressants with sufficient case reports for ocular neuromuscular disorders revealed that 33 were associated with such disorders, most notably mydriasis, miosis, and anisocoria.
CONCLUSION: This study delineates the ocular risks of antidepressants, highlighting higher toxicity for NDDIs and SSRIs and widespread associations with ocular neuromuscular disorders. Vigilant monitoring and early intervention are warranted to ensure safe clinical use.